文献速递肿瘤 PET/CT

基于2-[18F]FDG PET的淋巴结代谢异质性定量预测结直肠癌淋巴结转移

2-[18F]FDG PET-based quantification of lymph node metabolic heterogeneity for predicting lymph node metastasis in patients with colorectal cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-12-27

本研究利用264例术前行2-[18F]FDG PET/CT的结直肠癌患者数据构建影像组学模型,从淋巴结PET和CT图像提取特征,并在132例独立队列中验证。影像组学标签预测淋巴结转移的AUC为0.908,显著优于CT报告(AUC 0.563)和PET/CT报告(AUC 0.64)的淋巴结状态;识别N1和N2的AUC为0.885,同样显著优于传统方法。结论认为该标签较常规CT或PET/CT报告的淋巴结状态诊断性能更佳。

要点

  • 基于淋巴结PET/CT影像组学特征构建的标签预测淋巴结转移AUC为0.908。
  • 该标签识别N1和N2的AUC为0.885,显著优于CT和PET/CT报告。
  • 标签独立于临床危险因素,并在132例独立验证集中保持稳健。

核心结论

  • 基于2-[18F]FDG PET/CT、直接从淋巴结提取影像特征且不依赖临床危险因素的影像组学标签,较常规CT或PET/CT报告的淋巴结状态展现出更优的诊断性能,可用于术前识别结直肠癌患者的淋巴结转移状态并支持个体化预测。

研究设计与样本

  • 模型构建使用264例结直肠癌患者数据,所有患者均接受术前2-[18F]FDG PET/CT检查。
  • 从淋巴结的PET和CT图像提取影像组学特征,采用LASSO回归结合十折交叉验证筛选特征。
  • 通过ROC曲线分析将预测性能与传统方法(CT报告的淋巴结状态和PET/CT报告的淋巴结状态)进行比较。
  • 模型在2012年1月至2020年6月期间的132例独立队列中进行验证。

主要发现

  • 影像组学模型由8个显著影像组学特征组成(5个来自PET、3个来自CT),涵盖代谢和密度异质性。
  • 预测淋巴结阳性或阴性状态时,影像组学标签AUC为0.908,显著优于CT报告淋巴结状态(AUC 0.563,P < 0.001)和PET/CT报告淋巴结状态(AUC 0.64,P < 0.001)。
  • 识别N1和N2时,影像组学标签AUC为0.885,显著优于CT报告淋巴结状态(AUC 0.587,P < 0.001)和PET/CT报告淋巴结状态(AUC 0.621,P < 0.001)。
  • 该标签独立于临床危险因素,并在验证集中保持稳健;决策曲线分析证实其临床效用。

关键数值与推荐

  • 预测淋巴结阳性或阴性:影像组学标签AUC 0.908 vs CT报告AUC 0.563(P < 0.001)vs PET/CT报告AUC 0.64(P < 0.001)。
  • 识别N1和N2:影像组学标签AUC 0.885 vs CT报告AUC 0.587(P < 0.001)vs PET/CT报告AUC 0.621(P < 0.001)。
  • 影像组学模型包含8个显著特征,其中5个来自PET、3个来自CT。

临床怎么用

  • 原文结论指出该标签可实现术前淋巴结转移状态识别并支持结直肠癌患者淋巴结转移状态的个体化预测,原文未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: The pre-surgical estimation of lymph node (LN) metastasis in colorectal cancer (CRC) poses a significant diagnostic predicament. The associations between LN morphology, density, and metabolic heterogeneity and LN metastasis status in CRCs have been seldomly examined through the lens of radiomics. This research aimed to assess 2-[18F]FDG PET-based quantification of intratumoral metabolic heterogeneity for predicting lymph node metastasis in patients with colorectal cancer. MATERIALS AND METHODS: The construction of the model utilized data from 264 CRC patients, all of whom underwent preoperative 2-[18F]FDG PET/CT. Radiomic features were extracted from PET and CT images of LNs. Least absolute shrinkage and selection operator (LASSO) regression was implemented for selecting pertinent imaging features with a tenfold cross-validation. The predictive accuracy for LN metastasis status was juxtaposed against traditional methodologies (comprising CT-reported LN status and PET/CT-reported LN status) by deploying the receiver operating characteristic (ROC) curve analysis. The radiomics signature was evaluated based on discrimination, calibration, and clinical utility parameters. The model was further subjected to validation using an independent cohort of 132 patients from the period of January 2012 to June 2020. RESULTS: The radiomics model was composed of eight significant radiomic features (five from PET and three from CT), encapsulating metabolic and density heterogeneity. The radiomics signature (area under the curve (AUC), 0.908) showcased a significantly superior performance compared to CT-reported LN status (AUC, 0.563, P < 0.001) and PET/CT-reported LN status (AUC, 0.64, P < 0.001) for predicting LN-positive or LN-negative status. The radiomics signature (AUC, 0.885) also showcased a significantly superior performance compared to CT-reported LN status (AUC, 0.587, P < 0.001) and PET/CT-reported LN status (AUC, 0.621, P < 0.001) to identify N1 and N2. This signature maintained its independence from clinical risk factors and exhibited robustness in the validation test set. Decision curve analysis attested to the clinical utility of the radiomics signature. CONCLUSIONS: The radiomics signature based on 2-[18F]FDG PET/CT, which derived image features directly from LNs irrespective of clinical risk factors, displayed enhanced diagnostic performance compared to conventional CT or PET/CT-reported LN status. This allows for the identification of pre-surgical LN metastasis status and facilitates a patient-specific prediction of LN metastasis status in CRC patients.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Xu L, Huang G, Wang Y, et al. 2-[18F]FDG PET-based quantification of lymph node metabolic heterogeneity for predicting lymph node metastasis in patients with colorectal cancer. Eur J Nucl Med Mol Imaging. 2023. PMID: 38150017. doi:10.1007/s00259-023-06578-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。